Elanco Animal Health Incorporated

ELAN

US28414H1032

Pharmaceuticals

Market Closed - Nyse Other stock markets 02:30:02 21/01/2026 am IST			5-day change	1st Jan Change
24.16 ^USD	-1.51%		-1.19%	+6.76%

14/01	Elanco Animal Health Incorporated Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 03:45 PM
13/01	Elanco CEO: Gaining Market Share Via 'Major' Innovations	MT

Athian, Inc. announced that it has received $3.999989 million in funding from a group of investors

Published on 11/19/2025

S&P Capital IQ

ELANCO ANIMAL HEALTH INCORPORATED

-1.51%

MONDELEZ INTERNATIONAL, INC.

+1.31%

S&P GSCI AGRICULTURE INDEX

+0.32%

On November 19, 2025, Athian, Inc. has closed the transaction and it has received $3,999,989 in the transaction. The transaction include participation from new investors, Cultivate Next I, L.P., fund managed by NXP L.P., fund managed by Nextwave, Newtrient, LLC, Ajinomoto North America Holdings, Inc., Mondelez International, Inc., returning investors, Australian Agricultural and Property Management Limited, California Dairies, Inc., Elanco Animal Health Incorporated, DSM Venturing B.V. and Tyson Ventures, LLC. The transaction is being raised at a post-money valuation of $17,226,350.

Stocks mentioned in the article

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
ELANCO ANIMAL HEALTH INCORPORATED	24.16USD	-1.51%	-1.19%	1.2TCr
MONDELEZ INTERNATIONAL, INC.	57.99USD	+1.31%	+3.66%	7.48TCr
S&P GSCI AGRICULTURE INDEX	345.79PTS	+0.32%	-0.10%	-

Latest news about Elanco Animal Health Incorporated

14/01	Elanco Animal Health Incorporated Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 03:45 PM
13/01	Elanco CEO: Gaining Market Share Via 'Major' Innovations	MT
01/01	Elanco Animal Health Gets USDA Approval for Canine-Dermatitis Treatment	DJ
01/01	Elanco Animal Health Secures USDA Approval for Befrena Targeting Canine Allergic and Atopic Dermatitis	MT
01/01	Elanco Animal Health Incorporated Receives USDA Approval for Befrena?? (tirnovetmab)	CI
18/12	Elanco's Credelio Quattro??-CA1 (Lotilaner, Moxidectin, Praziquantel, and Pyrantel Chewable Tablets) Receives First FDA Conditional Approval for Treatment of New World Screwworm in Dogs	CI
18/12	Elanco Says Credelio Quattro-CA1 Got FDA Conditional Approval for Treatment of New World Screwworm in Dogs	MT
18/12	Elanco's Credelio Quattro(TM)-Ca1 receives first FDA conditional approval	RE
16/12	Virbac SA acquired Thyronorm from Norbrook Laboratories Limited in a transaction valued at ?100 million.	CI
10/12	Elanco Animal Health Incorporated - Analyst/Investor Day
09/12	Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday	MT
09/12	Elanco Animal Health Incorporated Announces Organizational Changes	CI
09/12	Elanco Animal Health Incorporated Announces Continued Investment in Its U.S. Operations, Workforce and Communities over the Next Five Years	CI
09/12	Elanco Animal Health Incorporated Announces Significant Progress in the Final Steps of the Approval of Befrena?	CI
09/12	Elanco Animal Health Incorporated to Seek M&A	CI
09/12	Elanco Animal Health Provides Guidance for 2026 Through 2028	MT
04/12	Elanco Animal Health Incorporated Presents at Piper Sandler 37th Annual Healthcare Conference, Dec-04-2025 08:30 AM
04/12	Elanco Animal Health Incorporated Presents at Evercore 8th Annual Healthcare Conference, Dec-03-2025 12:30 PM
26/11	Neurizon Therapeutics Limited Announces the Appointment of Justine Conway as Board Observer	CI
22/11	Elanco Gets FDA Emergency Approval for Treatment of New World Screwworm in Cats	MT
22/11	Fda issues emergency use authorization for Credelio Cat to treat New World screwworm in cats	RE
22/11	Elanco's drug gets emergency nod to treat deadly flesh-eating parasite in cats	RE
22/11	Elanco Animal Health Incorporated Receives First FDA Emergency Use Authorization for Treatment of New World Screwworm in Cats	CI
21/11	KeyBanc Initiates Elanco Animal Health at Overweight With $27 Price Target	MT
19/11	Argus Research Upgrades Elanco Animal Health to Buy From Hold, $25 Price Target	MT

Chart Elanco Animal Health Incorporated

Duration

Period

ELAN: Dynamic Chart

Company Profile

Elanco Animal Health Incorporated is an animal health company. The Company is focused on delivering products and services to prevent and treat disease in farm animals and pets. Its diverse, durable product portfolio serves animals across many species, primarily: dogs, cats and cattle, poultry, swine, and sheep. It offers products in two primary categories: Pet Health and Farm Animal. Its Pet Health portfolio is focused on parasiticides, vaccines and therapeutics. Its Pet Health portfolio has products that protect pets from fleas, ticks and internal parasites. Its Farm Animal portfolio of products is primarily focused on cattle, swine, and poultry. Its Pet Health products include Advantage Family, Atopica, Claro/ Neptra, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its Farm Animal products include AviPro, Baycox, Catosal, Comforta, Denagard, Experior, Hemicell, Maxiban, Monteban, Pulmotil, Rumensin, and others.

Employees

9,225

Sector

Pharmaceuticals

Calendar

25/02 - Q4 2025 Earnings Release (Projected)

More about the company